
Opinion|Videos|April 1, 2025
Subgroup Analyses and Clinical Insights in Metastatic Hormone-Sensitive Prostate Cancer Treatment
Jack R. Andrews, MD; Eugene B. Cone MD; and Edwin Posadas, MD, FACP, discuss how early intervention with individualized treatment approaches based on disease volume, patient characteristics, and biomarkers significantly improves survival outcomes in metastatic hormone-sensitive prostate cancer.
Advertisement
Episodes in this series

Timecodes
1:35 Individualized Care for PC
9:24 Frailty & Comorbidities in PC
12:27 Molecular Testing in PC
18:10 Sequencing in PC
22:00 Doublets/Triplets in mHSPC
30:00 Subgroups in mHSPC
39:00 ARASENS Subgroup Analysis
43:55 Future of mHSPC Care
Advertisement
Related to this article

Panelists answer audience questions on treatment targets, fertility-sparing options, and formulations, and why lifestyle change and therapy pair well.

Jonathan E. Rosenberg, MD, discusses the FDA approval of perioperative durvalumab plus enfortumab vedotin and considerations for treatment selection in cisplatin-ineligible MIBC.

Panelists challenge the belief that testosterone fuels prostate cancer, explain PSA on therapy and TRAVERSE BPH data, and weigh Schedule III status.

Jessica Feehan, NP-C, discusses the expanding role of APPs in urology, from clinical leadership and procedures to care coordination and treatment initiation.

Mohit Khera, MD, MBA, MPH, discusses preliminary research on radiofrequency therapy as a potential treatment for vasculogenic erectile dysfunction.

Sam S. Chang, MD, MBA, discusses treatment selection after BCG failure, including bladder-sparing options, cystectomy considerations, and the need for sequencing data.
Advertisement
Advertisement
Trending on Urology Times
1
LIB-01 enters phase 2b development for erectile dysfunction
2
Treatment Targets, Formulations, and the Future of Testosterone
3
Jonathan Rosenberg, MD, reacts to FDA approval of durvalumab plus EV for MIBC
4
Prostate Cancer, BPH, and Testosterone Scheduling Myths
5








